November 1, 2019
From the event website:
After decades of stalled progress, a new wave of clinical research involving psychedelic compounds shows promising results for treating depression, addiction, PTSD, and other mental health conditions.
MDMA is at the forefront of this psychiatric research; A multinational clinical trial of MDMA-assisted treatment for PTSD is currently underway in Canada, the US, and Israel. Sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), this research holds the potential to make MDMA available to the public as a medicine for use in conjunction with psychotherapy by 2023, revolutionizing treatment for one of humanity’s most debilitating forms of suffering.
This evening talk for the general public will use the presenter’s experiences as MDMA research therapists to introduce and explore this exciting new frontier in mental health care, including discussing drug effects, the accompanying psychotherapy protocol, and the MAPS research program.
After the presentation audience members will be invited to ask questions during an extended Q&A period.
Advance registration is required. This program can be attended alone or in conjunction with the presenters’ weekend program: Psychedelics 101 & 102 for Clinicians held November 2 & 3, also in Montreal.
If you have any questions, contact email@example.com.
For more information, visit the event website.